Research programme: antimalarials - GlaxoSmithKline/MMV

Drug Profile

Research programme: antimalarials - GlaxoSmithKline/MMV

Alternative Names: Amodiaquine analogues - GlaxoSmithKline/MMV; Azithromycin-based antimalarials - GlaxoSmithKline/MMV; carboxamides - GlaxoSmithKline/MMV; Cysteine protease inhbitors - GlaxoSmithKline/MMV; Enoyl-ACP reductase inhibitors - GlaxoSmithKline/MMV; GSK-369796; GW 308678; Isoquine analogues - GlaxoSmithKline/MMV

Latest Information Update: 18 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Medicines for Malaria Venture
  • Developer GlaxoSmithKline; Medicines for Malaria Venture; University of California at San Francisco
  • Class Aminoquinolines; Erythromycins; Pyridones
  • Mechanism of Action Cysteine endopeptidase inhibitors; Dihydroorotate dehydrogenase inhibitors; Electron transport complex I inhibitors; Enoyl-ACP reductase inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 18 Apr 2011 Preclinical development is ongoing in the US and Spain
  • 23 Mar 2010 Preclinical development is ongoing in USA and Spain
  • 10 Sep 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top